Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mencevax ACWY · 1 trial · 1 indication
Vaccine response defined as: for initially seronegative subjects, antibody titer greater than or equal to (≥) 1:32 and for initially seropositive subjects: antibody titer ≥ 4 fold the pre-vaccination antibody titer. The analysis was performed with the GSK rSBA assay.
Titers are presented as geometric mean titers (GMTs). All subjects underwent testing with the GSK rSBA assay for all 4 serogroups.
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Group C | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Mencevax ACWY | BIOLOGICAL | One dose, Subcutaneous injection |
| GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612] | BIOLOGICAL | One dose, Intramuscular injection |
Inclusion Criteria: All subjects must satisfy all of the following criteria at study entry: * Subjects whom the investigator believes they can and will comply with the requirements of the protocol will be enrolled in the study. * A male or female between, and including, 18 and 25 years of age the ...
Mencevax ACWY is a vaccine developed by GSK plc for the prevention of meningococcal infections. It is a Phase 3 candidate studied in healthy adults aged 18 to 25 years. Mencevax ACWY has been evaluated in a single completed clinical trial with 1,170 participants across Panama, the Philippines, and Thailand.
Mencevax ACWY is used for protection against meningococcal infections. Its clinical development has focused on healthy adults aged 18 to 25 years. The only registered trial of Mencevax ACWY studied immunization against meningococcal disease in this age group across sites in Panama, the Philippines, and Thailand.
Mencevax ACWY is made by GSK plc, which trades under the ticker GSK. GSK is the developer of the vaccine and sponsored the Phase 3 trial evaluating it. The study compared the immunogenicity and safety of another meningococcal vaccine candidate, GSK 134612, against Mencevax ACWY as the active control.
Mencevax ACWY has been studied in Phase 3 clinical development. Its single registered trial, NCT01154088, is completed, and no trials of Mencevax ACWY are currently active. The Phase 3 study enrolled 1,170 healthy adults aged 18 to 25 years and used a randomized, double-blind, active-controlled design.
Mencevax ACWY was evaluated in one completed Phase 3 trial, NCT01154088, titled Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax ACWY in Healthy 18-25 Year Olds. The trial enrolled 1,170 healthy volunteers of all sexes in Panama, the Philippines, and Thailand and was randomized, double-blind, and active-controlled.
Yes. Mencevax ACWY, MencevaxACWY, Mencevax-ACWY, and the trademarked forms Mencevax ACWY and Mencevax ACWY all refer to the same GSK plc meningococcal vaccine candidate. The spacing, hyphenation, and trademark symbols are formatting variations of the same product name used across sources.